Eribulin Monomethanesulfonate
Bladder Transitional Cell Carcinoma
Explore 37 assets in Bladder Transitional Cell Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03237780CT.gov Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bladder Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eribulin Monomethanesulfonate (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BB |
| Atezolizumab | KaliVir Immunotherapeutics | P3 | BB |
| Carboplatin | Jonsson Comprehensive Cancer Center | P2 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2 | BB |
| Nivolumab | Nagoya University | P3 | BB |
| Durvalumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Adriamycin | University of Southern California | P2 | B |
+42 more in the Bladder Transitional Cell Carcinoma cohort
Other indications for Eribulin Monomethanesulfonate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P4 | BB · 69 |
| Breast Cancer | — | P4 | BB · 69 |
| Toxic Encephalopathy | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Cis-Diamminedichloroplatinum IiNagoya UniversityBB
- AtezolizumabKaliVir ImmunotherapeuticsBB
- CarboplatinJonsson Comprehensive Cancer CenterBB
- PembrolizumabFred Hutchinson Cancer CenterBB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Eribulin Monomethanesulfonate in Bladder Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eribulin-monomethanesulfonate-bladder-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →